Potential impact of combined high-and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2

Journal of Obstetrics and Gynaecology Research

Volumn 40, Issue 2, 2014, Pages 561-569

  Okadome, Masao ^a   Saito, Toshiaki ^a   Tanaka, Hideyuki ^b   Nogawa, Takayoshi ^d   Furuta, Reiko ^b   Watanabe, Kayoko ^b   Kita, Tsunekazu ^e   Yamamoto, Kaichiro ^f   Mikami, Mikio ^g   Takizawa, Ken ^c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cervical intraepithelial neoplasia; Human papillomavirus; Infection screening; Management of precancer; Virus genotyping

Indexed keywords

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; COHORT ANALYSIS; COLPOSCOPY; CYTOLOGY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; INFECTION RATE; INFECTION RISK; JAPAN; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROSPECTIVE STUDY; TUMOR INVASION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMA VIRUS; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COINFECTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84897977713     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12202     Document Type: Article

References (24)

1. Nagai Y, Toma T, Moromizato H et al. Persistence of human papillomavirus infection as a predictor for recurrence in carcinoma of the cervix after radiotherapy. Am J Obstet Gynecol 2004; 191: 1907-1913.
2. zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-F78.
3. Matsumoto K, Oki A, Furuta R et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011; 128: 2898-2910.
4. Östör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-192.
5. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92: 727-735.
6. Holowaty P, Miller A, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252-258.
7. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197: 356.e1-356.e6.
8. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 18-25.
9. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-1488.
10. Schiffman M, Herrero R, Desalle R et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
11. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
12. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079.
13. Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006; 194: 1291-1299.
14. Trottier H, Mahmud S, Costa MC et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-1280.
15. Herrero R, Castle PE, Schiffman M et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796-1807.
16. Cuschieri KS, Cubie HA, Whitley MW et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005; 58: 946-950.
17. Luostarinen T, af Geijersstam V, Bjørge T et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999; 80: 818-822.
18. Silins I, Wang Z, Åvall-Lundqvist E et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 1999; 80: 2931-2936.
19. Franco EL, Villa LL, Sobrinho JP et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415-1423.
20. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 1999; 73: 6188-6190.
21. Combelas N, Saussereau E, Fleury MJ et al. Papillo-mavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. J Transl Med 2010; 8: 28.
22. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-105.
23. Carreon JD, Sherman ME, Guillen D et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441-446.
24. Furuta R, Hirai Y, Katase K et al. Ectopic chromosome around centrosome in metaphase cells as a marker of high-risk human papillomavirus-associated cervical intraepithelial neoplasias. Int J Cancer 2003; 106: 167-171.